Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1533 - DNA repair gene expression in bronchial washing fluid as new molecular tool for clinical outcome decision


09 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Translational Research;  Thoracic Malignancies


Diana Schveigert


Annals of Oncology (2017) 28 (suppl_5): v457-v459. 10.1093/annonc/mdx379


D. Schveigert1, R. Askinis2, J. Fadejeva1, V. Sapoka3, A. Krasauskas2, S. Cicenas2

Author affiliations

  • 1 Laboratory Of Molecular Oncology, National Cancer Institute, LT-08406 - Vilnius/LT
  • 2 Department Of Thoracic Surgery And Oncology, National Cancer Institute, LT-08660 - Vilnius/LT
  • 3 Clinics Of Internal Diseases, Vilnius University hospital Santariskiu Klinikos, LT-08661 - Vilnius/LT


Abstract 1533


Platinum-based drugs (cisplatin, etc.) are used as a first-line therapy for NSCLC patients. However, such treatment is not effective for all patients. Biomarkers that could predict efficiency of the platinum-based treatment should be identified. Aim: To evaluate whether the response to treatment of NSCLC patients is based on ERCC1 and RRM1 gene expression in bronchial washing fluid.


70 patients with a first-time diagnosed NSCLC receiving Cisplatin+Etoposid were involved in the study. RNA was extracted from bronchial washing fluid using “RNeasy Plus Mini Kit” (QIAGEN, Germany). The analysis of ERCC1 and RRM1 expression was done by qRT-PCR method. A χ2 test was used to analyze gene expression in relation to clinicopathological parameters. The survival rates were calculated by the Kaplan-Meier method. The prognostic significance was assessed by the Cox proportional hazards regression model.


Statistically significant differences were found between ERCC1 expression and tumour differentiation grade, RRM1 expression and disease stage and lymph node status. ERCC1 expression was associated with NSCLC patient progression-free survival (PFS) rate depending on gender, disease stage, response to treatment. Patients from high ERCC1 expression group had 7.6 months longer survival than patients from low expression group. RRM1 expression was associated with NSCLC patients PFS rates depending on gender, age, tumour histology and differentiation grade. Patients from low RRM1 expression group had 7.9 months longer survival than those from high expression group. Multivariate analysis of factors influencing PFS rate showed that disease stage (p = 0.01), tumor differentiation grade (p = 0.009), response to treatment (p = 0.02) and RRM1 expression (p = 0.001) were independent prognostic factors of NSCLC patients PFS.


ERCC1 and RRM1 genes may influence platinum-based chemotherapy treatment of NSCLC patients. In order to improve the effectiveness of treatment it is appropriate to identify RRM1 expression changes in the bronchial washing fluid. Therefore, NSCLC patients with high RRM1 expression should be actively followed-up because of quicker disease progression.

Clinical trial identification

Lithuanian Bioethics Committee No. 158200-09-381-104

Legal entity responsible for the study

National Cancer Institute




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.